|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2011-1-12
|
|
pubmed:abstractText |
The aim of this study was to determine whether the expressions of excision repair cross-complementing-1 (ERCC1) and thymidylate synthase (TS) predict the clinical outcome of patients with esophageal squamous cell carcinoma treated with CDDP/5-FU chemoradiotherapy.
|
|
pubmed:language |
jpn
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/ERCC1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Endonucleases,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53,
http://linkedlifedata.com/resource/pubmed/chemical/bcl-2-Associated X Protein
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0385-0684
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2394-6
|
|
pubmed:meshHeading |
pubmed-meshheading:21224584-Aged,
pubmed-meshheading:21224584-Antimetabolites, Antineoplastic,
pubmed-meshheading:21224584-Antineoplastic Agents,
pubmed-meshheading:21224584-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21224584-Carcinoma, Squamous Cell,
pubmed-meshheading:21224584-Cisplatin,
pubmed-meshheading:21224584-Combined Modality Therapy,
pubmed-meshheading:21224584-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:21224584-DNA-Binding Proteins,
pubmed-meshheading:21224584-Endonucleases,
pubmed-meshheading:21224584-Esophageal Neoplasms,
pubmed-meshheading:21224584-Female,
pubmed-meshheading:21224584-Fluorouracil,
pubmed-meshheading:21224584-Humans,
pubmed-meshheading:21224584-Immunohistochemistry,
pubmed-meshheading:21224584-Male,
pubmed-meshheading:21224584-Middle Aged,
pubmed-meshheading:21224584-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:21224584-Thymidylate Synthase,
pubmed-meshheading:21224584-Treatment Outcome,
pubmed-meshheading:21224584-Tumor Suppressor Protein p53,
pubmed-meshheading:21224584-bcl-2-Associated X Protein
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
[ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
|
|
pubmed:affiliation |
Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
